Trastuzumab Cardiac Dysfunction Risk Low in HERA Patients

Long-term cardiac toxicity rates are low for patients given trastuzumab after other treatment modalities are completed. 

ESMO members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.